Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

PURPOSE: B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. PATIENTS A...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Davids, Matthew S., Roberts, Andrew W., Seymour, John F., Pagel, John M., Kahl, Brad S., Wierda, William G., Puvvada, Soham, Kipps, Thomas J., Anderson, Mary Ann, Salem, Ahmed Hamed, Dunbar, Martin, Zhu, Ming, Peale, Franklin, Ross, Jeremy A., Gressick, Lori, Desai, Monali, Kim, Su Young, Verdugo, Maria, Humerickhouse, Rod A., Gordon, Gary B., Gerecitano, John F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2017
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455685/
https://ncbi.nlm.nih.gov/pubmed/28095146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.4320
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller